Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2010

01-10-2010 | Editorial Commentary

Interim PET in lymphoma: a step towards standardization

Author: Michel Meignan

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2010

Login to get access

Excerpt

In this issue, Barrington et al. propose well-defined criteria for interim PET/CT reporting in lymphoma [1]. These criteria, based on a five-point scale, introduce two main concepts which are highly relevant for interim PET analysis: (1) the intensity of the residual uptake frequently observed at interim is graded relative to various levels of reference background (RB)—mediastinal blood pool (MBP) and liver—and (2) this grading process is independent of the size of the residual tumour. Furthermore, the authors reported that this five-point scale assessed on a sample of 50 patients with advanced stage Hodgkin’s lymphoma (HL) by 4 pairs of experts from 4 European centres: (1) seems a reproducible tool for guiding therapeutic strategy after 2 cycles of ABVD (Adriamycin,bleomycin, vinblastine, dacarbazine) when liver is chosen as an RB and (2) is robust enough to be used in multicentre trials for interim PET reporting. …
Literature
1.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010. doi:10.​1007/​s00259-010-1490-5.PubMed
2.
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–8.CrossRefPubMed
3.
Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48(10):1626–32.CrossRefPubMed
4.
Meignan M, Itti E, Gallamini A, Haioun C. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand? Leuk Lymphoma 2009;50(11):1753–6.CrossRefPubMed
5.
Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50(4):527–33.CrossRefPubMed
6.
Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50(11):1761–4.CrossRefPubMed
7.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359(22):2313–23.CrossRefPubMed
8.
Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010;7(6):301–2.CrossRefPubMed
9.
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25(24):3746–52.CrossRefPubMed
10.
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28(11):1896–903.CrossRefPubMed
11.
Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106(4):1376–81.CrossRefPubMed
12.
Andre MPE, Reman O, Fédérico M, Brice P, Brusamolino E, Girinski T, et al. First report on the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin’s Lymphoma, for the Groupe d’Etude Des Lymphomes De l’Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). ASH Annu Meet Abstr 2009;114(22):97.
13.
Horning SJ, Juweid ME, Schöder H, Wiseman G, McMillan A, Swinnen LJ, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010;115(4): 775–7.CrossRefPubMed
14.
Itti E, Juweid M, Haioun C, Yeddes I, Hamza F, El Bez I, et al. Improvement of early FDG-PET interpretation in diffuse large B-cell lymphoma (DLBCL): importance of the reference background. J Nucl Med 2010;51:97P–8P.
15.
Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50(8):1257–60.CrossRefPubMed
Metadata
Title
Interim PET in lymphoma: a step towards standardization
Author
Michel Meignan
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1546-6

Other articles of this Issue 10/2010

European Journal of Nuclear Medicine and Molecular Imaging 10/2010 Go to the issue

Guidelines

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

Original Article

PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG

Original Article

Real-time breath-hold triggering of myocardial perfusion imaging with a novel cadmium-zinc-telluride detector gamma camera

Original Article

Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer

Society communications

EANM YIM 2010—Report

Review Article

A review on the clinical uses of SPECT/CT